Table 3.
Incidence of ADRs as reported within the VigiAccess/VigiBase from the World Health Organization global database for ADRs.
| Drug | Total ADRs, n | Cardiac ADRs, n (%) | Proportion of cardiac ADRs |
|||
|---|---|---|---|---|---|---|
| Myocarditis, n (%) | Pericardial disease, n (%) | Conduction abnormalities, n (%) | Stress cardiomyopathy, n (%) | |||
| Pembrolizumab | 25,028 | 497 (1.99) | 80 (16.10) | 80 (16.10) | 34 (6.84) | 5 (1.00) |
| Nivolumab | 49,506 | 1103 (2.23) | 148 (13.40) | 155 (14.10) | 71 (6.44) | 6 (0.54) |
| Atezolizumab | 3627 | 94 (2.59) | 10 (10.60) | 16 (17.00) | 6 (6.38) | 1 (1.06) |
| Avelumab | 505 | 16 (3.17) | 4 (25.00) | 2 (12.50) | 2 (12.50) | 0 (0.00) |
| Durvalumab | 1329 | 34 (2.56) | 4 (11.80) | 7 (11.80) | 0 (0.00) | 0 (0.00) |
| Ipilimumab | 26,030 | 471 (1.81) | 69 (14.60) | 42 (8.92) | 39 (8.28) | 4 (0.85) |
| Total | 106,025 | 2215 (2.09) | 312 (14.10) | 302 (13.60) | 152 (6.86) | 16 (0.72) |
ADR: adverse drug reactions.